Molecular Aspects of Resistance to Immunotherapies—Advances in Understanding and Management of Diffuse Large B-Cell Lymphoma

Despite the unquestionable success achieved by rituximab-based regimens in the management of diffuse large B-cell lymphoma (DLBCL), the high incidence of relapsed/refractory disease still remains a challenge. The widespread clinical use of chemo-immunotherapy demonstrated that it invariably leads to...

Descripción completa

Detalles Bibliográficos
Autores principales: Kusowska, Aleksandra, Kubacz, Matylda, Krawczyk, Marta, Slusarczyk, Aleksander, Winiarska, Magdalena, Bobrowicz, Malgorzata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8835809/
https://www.ncbi.nlm.nih.gov/pubmed/35163421
http://dx.doi.org/10.3390/ijms23031501

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8835809/
https://www.ncbi.nlm.nih.gov/pubmed/35163421
http://dx.doi.org/10.3390/ijms23031501

Ejemplares similares